Type 2 Diabetes Mellitus (hereinafter – DM 2) is the most common endocrine disorder, and its prevalence in Europe, the USA and Canada is 8% of the total adult population. The incidence of DM 2 in the world is increasing every year, and real growth rates outperform all forecasts. In 2009 it was expected that by 2025 the number of patients with DM 2 in the world will reach 380 million. However, there are 380 million people with DM 2 now (2018) according to the International Diabetic Federation. Adjusted forecasts of specialists are even more debilitating as their prognosis is 550 million patients with DM 2 up to 2030. The purpose of the study was to summarize data on the role of metabolic disturbances, oxidative stress and endothelial dysfunction in the formation of micro- and macrovascular complications of DM 2. Results and discussion. We examined the main pathogenetic mechanisms and risk factors for the development of cardiovascular complications of DM 2, its relationships and comorbidity with ischaemic heart disease, arterial hypertension and chronic cardiac insufficiency. Significant importance of hyperglycaemia, insulin resistance, lipid metabolic disturbances, haemostasis, proteinuria and albuminuria is emphasized, the above factors facilitating the development of DM 2 complications and their clinical manifestation and considerably worsening the course of the disease. As a rule, a patient with DM 2 has several cardiovascular risk factors, so each of them should be adjusted according to existing recommendations. Patients with DM 2 require special monitoring of cardiologists and endocrinologists, a more careful approach to the choice of therapy and prevention of cardiovascular complications. Accordingly, treatment of patients in this category should include both the correction of metabolic disorders and the influence on risk factors for the development of cardiovascular pathology. Having analyzed the data on metabolic disturbances, oxidative stress and endothelial dysfunction in the formation of micro- and macrovascular complications of DM 2 we distinguished several preventive and therapeutic actions. These actions are aimed at correction of these factors in order to prevent the development and progression of cardiovascular complications of DM 2. According to the results of the NAVIGATOR study, patients with impaired glucose tolerance and other cardiovascular risk factors that had a series of glycemic tests, diuretics and statins, were associated with an increased risk of developing the first identified DM 2 while the effect of beta-blockers was negligible. The use of a fixed combination of perindopril, indapamide and calcium channel blockers in patients with hypertension and DM 2 (ADVANCE study) contributed to a reduction in the relative risk of adverse cardiovascular events, and also provided an additional reduction in mortality in patients with DM 2. Conclusion. Thus, the correction of the above mentioned risk factors, as well as modification of the lifestyle, will help to prevent the onset or delay of the progression of complications of DM 2 by the cardiovascular system, which in turn will improve the quality of life and prognosis in these patients.

Keywords: diabetes mellitus type 2, cardiovascular complications, pathogenesis, prognosis, prevention

Full text: PDF (Ukr) 297K

1. Ametov AS. Vklad sovremennykh yssledovanyy v ponymanye pryrody sakharnogo dyabeta 2-go typa y perspektyvy lechenyya. Terapevtycheskyy arkhyv. 2014; 1: 4-9. [Russian]
2. Akhmedova ShU, Kadyrova ZS. Osobennosty porazhenyya pochek u bolnykh sakharnym dyabetom 2-go typa s ozhyrenyem. Mezhdunarodnyy endokrynologycheskyy zhurnal. 2017; 17(2): 177-80. [Russian]
3. Babyy LN, Stroganova NP, Khomenko YuO. Dyastolycheskaya dysfunktsyya levogo zheludochka serdtsa y eyo rol v razvytyy serdechnoy nedostatochnosty u bolnykh yshemycheskoy boleznyu serdtsa. Ukr kardiol zhurn. 2017; 3: 20-6. [Russian]
4. Voronkov LG. Myldronat: mekhanyzmy deystvyya y oblasty prymenenyya. Zdorov’ya Ukrayiny. 2017; 15-16: 1-3. [Russian]
5. Goldobin PO. Psykhologichnyy ta nutrytsiologichnyy pidkhody do modyfikatsiyi stylyu zhyttya pry tsukrovomu diabeti. Ukr med chasopys. 2017; 5(121): 1-3. [Ukrainian]
6. Goryushkyna OA, Vasyleva EM. Antyoksydantnaya terapyya v korrektsyy oksydatyvnogo stressa u bolnykh yshemycheskoy boleznyu serdtsa s sakharnym dyabetom 2-go typa. Vestnyk novykh medytsynskykh tekhnologyy. 2013; XX(2): 156. [Russian]
7. Degtyar NY, Gerasymenko ND, Rasyn MS. Endotelyy y systemnoe vospalenye: rol yadernykh transkryptsyonnykh faktorov y terapevtycheskye vozmozhnosty (obzor lyteratury). Arteryalnaya gypertenzyya. 2016; 4(48): 21-5. [Russian]
8. Yena LM, Yarosh VO, Artemenko VO, Khrystoforova GM. Gormonalnyy gomeostaz ta yogo vzayemozv’yazok iz morfofunktsionalnym stanom sertsevo-sudynnoyi systemy u khvorykh na khronichnu sertsevu nedostatnist zi zberezhenoyu fraktsiyeyu vykydu. Sertseva nedostatnist ta komorbidni stany. 2017; 3: 42-6. [Ukrainian]
9. Zharynova VYu, Ygrunova KN, Bodretskaya LA, y dr. Prymenenye orygynalnogoL-ornytyna-L-aspartata u bolnykh s kompleksnoy kardyovaskulyarnoy patologyey y sakharnym dyabetom 2-go typa. Mizhnarodn endokryn zhurn. 2015; 8(72): 33-41. [Russian]
10. Zhuravleva LV, Lopyna NA. Vlyyanye kombynyrovannoy terapyy s prymenenyem alfa-lypoevoy kysloty na uroven fraktalkyna u bolnykh yshemycheskoy boleznyu serdtsa y sakharnym dyabetom 2-go typa. Mizhnarodn endokryn zhurn. 2016; 7(79): 75-81. [Russian]
11. Zanozyna OV, Sorokyna YuA, Borovkov NN, Shcherbatyuk TG. «Porochnyy krug» vzaymosvyazy perekysnogo okysnenyya lypydov y okyslytelnoy modyfykatsyy belkov u bolnykh sakharnym dyabetom 2 typa. Medytsynskyy almanakh. 2013;  6: 167-70. [Russian]
12. Kaminskyy OV. Ofitsiyni kryteriyi diagnostyky tsukrovogo diabetu, normoglikemiya i samokontrol glikemiyi. Mizhnarodn endokryn zhurn. 2017; 13(3): 184-90. [Ukrainian]
13. Kyyak YuG, Kyyak GYu, Barnett OYu. Spetsyfichnist diabetychnoyi kardiomiopatiyi za nayavnosti komorbidnykh sertsevo-sudynnykh zakhvoryuvan: kliniko-ultrastrukturni doslidzhennya. Mizhnarodn endokryn zhurn. 2016; 5(77): 33-8. [Ukrainian]
14. Kovalenko VN, Dolzhenko MN, Nesukay EG, Dyachenko YaS. Sravnytelnaya kharakterystyka profylaktyky serdechno-sosudystykh zabolevanyy v Ukrayne y Evrope po dannym EUROASPIREIV: gospytalnaya lynyya. Arteryalnaya gypertenzyya. 2015; 5(43): 57-61. [Russian]
15. Kolesnyk M. Sakharnyy dyabet y drugaya endokrynnaya patologyya v vozrastnom aspekte: metody lechenyya. Ukr med chasopys. 2017 (KhI/KhII); 6(122): 1-4. [Russian]
16. Kolesnyk M. Sakharnyy dyabet y drugye endokrynnye zabolevanyya: sovremennye vozmozhnosty lechenyya. Ukr med chasopys. 2018 (V/VI); 1(124): 1-4. [Russian]
17. Konopleva LF. Endotelyalnaya dysfunktsyya v patogeneze serdechno-sosudystykh zabolevanyy y metody ee korrektsyy. Ukr med visnyk. 2011; 3(56): 26-30. [Russian]
18. Kravchun NO, Chernyayeva AO. Remodelyuvannya miokarda v patsiyentiv iz tsukrovym diabetom 2-go typu v poyednanni z nealkogolnoyu zhyrovoyu khvoroboyu pechinky. Mizhnarodn endokryn zhurn. 2015; 8(72): 88-94. [Russian]
19. Levykh AE, Mamchur VY. Atsetylsalytsylovaya kyslota kak effektyvnaya y bezopasnaya osnova antyagregantnoy terapyy. Arteryalnaya gypertenzyya. 2015; 6(44): 57-63. [Russian]
20. Malachkova NV, Komarovskaya YV, Kyrylyuk ML. Uroven glykemyy y ynsulynorezystentnosty u bolnykh s sakharnym dyabetom 2-go typa, dyabetycheskoy retynopatyey y ozhyrenyem. Mezhdunarodn endokryn zhurn. 2017; 13(3): 129-34. [Russian]
21. Malyar KYu, Anisimova OS, Drishlyuk OI, ta in. Efektyvnist preparatu Vazonat u skladi kompleksnoyi terapiyi patsiyentiv iz tsukrovym diabetom 2-go typu na tli sertsevo-sudynnoyi patologiyi. Mizhnarodn endokryn zhurn. 2018; 14(1): 86-92. [Ukrainian]
22. Martyshyn OO. Metabolichni, endokrynni ta sertsevo-sudynni zakhvoryuvannya: mizhdystsyplinarnyy pidkhid do diagnostyky ta likuvannya. Ukr med chasopys. 2017 (XI/XII); 6(122): 1-4. [Ukrainian]
23. Masik NP, Kalandey KYa. Poshyrenist metabolichnogo syndromu u khvorykh terapevtychnogo statsionaru z gipertonichnoyu khvoroboyu. Ukr terapevt zhurn. 2017; 4: 40-5. [Ukrainian]
24. Mokryy VYa, Zyablitsev SV, Borys RM. Porushennya systemy perekysnogo okysnennya lipidiv pry tsukrovomu diabeti 2-go typu (oglyad literatury). Mizhnarodn endokryn zhurn. 2015; 7(71): 41-4. [Ukrainian]
25. Muravlova OV. Tsukrovyy diabet 2-go typu v praktytsi likarya simeynoyi medytsyny. Mizhnarodn endokryn zhurn. 2015; 3(67): 122-4. [Ukrainian]
26. Nesukay EG. Vozmozhnosty sartanov v lechenyy arteryalnoy gypertenzyy y komorbydnykh sostoyanyy: vybor olmesartana. Arteryalnaya gypertenzyya. 2016; 2(46): 11-20. [Russian]
27. Nikolayenko VB. Sertsevo-sudynni zakhvoryuvannya: suchasni pidkhody do likuvannya. Ukr med chasopys. 2018 (III/IV); 123: 16-21. [Ukrainian]
28. Obrezan AG, Bytsadze RM. Struktura serdechno-sosudystykh zabolevanyy u bolnykh sakharnym dyabetom 2-go typa, dyabetycheskaya kardyomyopatyya kak osoboe sostoyanye myokarda. Mezhdunarod endokryn zhurn. 2010; 4: 18-22. [Russian]
29. Osadchyy OI. Sertseva nedostatnist i komorbidnist. Suchasnyy stan ta perspektyvy likuvannya. Ukr med chasopys. 2018 (VII/VIII); 2(124): 1-3. [Ukrainian]
30. Pankiv VI. Farmakoterapevtychna efektyvnist i perevagy kombinovanogo likuvannya khvorykh na tsukrovyy diabet 2-go typu. Mizhnarodn endokryn zhurn. 2017; 13(6): 435-9. [Ukrainian]
31. Pankiv VI. Novi rekomendatsiyi Amerykanskoyi diabetychnoyi asotsiatsiyi 2018 roku z diagnostyky ta likuvannya tsukrovogo diabetu. Mizhnarodn endokryn zhurn. 2018; 14(1): 93-8. [Ukrainian]
32. Prybyla OV, Zynych OV, Melua GA. Oblyteryruyushchyy ateroskleroz arteryy nyzhnykh konechnostey – neotsenennaya opasnost pry sakharnom dyabete. Ukr med chasopys. 2018 (III/IV); 2(124): 1-4. [Russian]
33. Radchenko AD. Chto takoe ratsyonalnaya kombynyrovannaya antygypertenzyvnaya terapyya y ostaetsya ly takovoy kombynatsyya yngybytora APF y dyuretyka? Arteryalnaya gypertenzyya. 2014; 1(33): 71-85. [Russian]
34. Radchenko AD. Dyuretyky v lechenyy arteryalnoy gypertenzyy: tak ly ony plokhy y vse ly odynakovy? Arteryalnaya gypertenzyya. 2016; 2(46): 26-34. [Russian]
35. Radchenko OM, Korolyuk OYa. Osoblyvosti perebigu ta likuvannya ishemichnoyi khvoroby sertsya u khvorykh z porushennyamy metabolizmu glyukozy ta tsukrovym diabetom. Mizhnarodn endokryn zhurn. 2015; 6(70): 11-6. [Ukrainian]
36. Savchenko IP. Optymizatsiya diagnostyky i likuvannya khvorykh na uskladnenyy infarkt miokarda iz tsukrovym diabetom 2-go typu. Mizhnarodn endokryn zhurn. 2015; 3(67): 161-5. [Ukrainian]
37. Sergyenko VA, Sergyenko AA. Dyabetycheskaya kardyalnaya avtonomnaya neyropatyya: kakovy perspektyvy v lechenyy? Arteryalnaya gypertenzyya. 2016; 1(45): 13-28. [Russian]
38. Seryk SA. Aspyryn v pervychnoy y vtorychnoy profylaktyke serdechno-sosudystykh zabolevanyy: effektyvnost y bezopasnost. Ratsionalna Farmakoterapiya. 2017; 3(44): 1-4. [Russian]
39. Skorykova SL. Vozmozhnosty sovremennoy ynsulynoterapyy v dostyzhenyy nayluchshykh terapevtycheskykh rezultatov u bolnykh sakharnym dyabetom. Ukr med chasopys. 2018 (V/VI); 2(124): 97-101. [Russian]
40. Sokolova LK, Pushkaryov VM, Kovzun EY, Pushkaryov VV, Tronko ND. Sakharnyy dyabet y ateroskleroz: epygenetycheskye mekhanyzmy patogeneza. Obzor lyteratury. Ukr kardiol zhurn. 2017; 6: 104-17. [Russian]
41. Stabilna ishemichna khvoroba sertsya (adaptovana klinichna nastanova, zasnovana na dokazakh, 2016). Arterialna gipertenziya. 2016; 2(46): 113-26. [Ukrainian]
42. Fadyeyenko GD, Nesen AO, Babenko OV. Mozhlyvosti prognozuvannya i profilaktyky rozvytku komorbidnosti sertsevo-sudynnykh zakhvoryuvan i tsukrovogo diabetu 2 typu v populyatsiyi osib pidvyshchenogo kardiovaskulyarnogo ryzyku. Ukr terapevt zhurn. 2016; 2: 14-21. [Ukrainian]
43. Khyzhnyak OO, Mykytyuk MR, Karachentsev YuI. Likuvannya diabetychnoyi polineyropatiyi. Mizhnarodn endokryn zhurn. 2017; 13(1): 65-9. [Ukrainian]
44. Chernyavska IV. Profil chynnykiv ryzyku sertsevo-sudynnykh zakhvoryuvan pry ishemichniy khvorobi sertsya v osib iz normalnym i porushenym vuglevodnym obminom. Mizhnarodn endokryn zhurn. 2015; 8(72): 83-7. [Ukrainian]
45. Chursyna TYa, Mykhalev KA. Atsetylsalytsylovaya kyslota v pervychnoy profylaktyke serdechno-sosudystykh oslozhnenyy cherez pryzmu effektyvnosty y bezopasnosty. Ukr med visnyk. 2011; 3(56): 68-70. [Russian]
46. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2017; 40(Suppl 1): 135 p.
47. American Diabetes Association’s Standards of Medical Care in Diabetes – 2018. Diabetes Care. 2018; 41(Suppl 1): S1-S159. https://doi.org/10.2337/dc18-Sint01
48. Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, et al. Diabetes Prevention Program Research Group. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016; 101: 1754-61. https://www.ncbi.nlm.nih.gov/pubmed/26900641. https://www.ncbi.nlm.nih.gov/pmc/articles/4880159. https://doi.org/10.1210/jc.2015-3754
49. Arror AR, Mandavia CH, Sowers JR. Insulin resistance and heart failure : molecular mechanisms. Heart Fail Clin. 2012; 8(4): 3133-40. https://www.ncbi.nlm.nih.gov/pubmed/22999243. https://www.ncbi.nlm.nih.gov/pmc/articles/3457065. https://doi.org/10.1016/j.hfc.2012.06.005
50. Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016; 352: i438. https://doi.org/10.1136/bmj.i438
51. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012; 380: 37-43. https://www.ncbi.nlm.nih.gov/pubmed/22579043. https://doi.org/10.1016/S0140-6736(12)60240-2
52. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004; 27: 699-703. https://www.ncbi.nlm.nih.gov/pubmed/14988288. https://doi.org/10.2337/diacare.27.3.699
53. de Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017; 40: 1273-84. https://www.ncbi.nlm.nih.gov/pubmed/28830958. https://doi.org/10.2337/dci17-0026
54. Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analysis. BMJ. 2016; 352: 717. https://doi.org/10.1136/bmj.i717
55. Bugger H, Abel DE. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014; 57(4): 660-71. https://www.ncbi.nlm.nih.gov/pubmed/24477973. https://www.ncbi.nlm.nih.gov/pmc/articles/3969857. https://doi.org/10.1007/s00125-014-3171-6
56. Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, et al. Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analysis. PLoS Med. 2016; 13: e1001971. https://www.ncbi.nlm.nih.gov/pubmed/26954482. https://www.ncbi.nlm.nih.gov/pmc/articles/4783064. https://doi.org/10.1371/journal.pmed.1001971
57. Chalmers J, Arima H, Woodward M, Mancia G, Poulter N, Hirakawa Y, et al. Effects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus: Results From the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) Trial. Hypertension. 2014; 63(2): 259-64. https://www.ncbi.nlm.nih.gov/pubmed/24324048. https://doi.org/10.1161/HYPERTENSIONAHA.113.02252
58. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 2006; 348: 952-7. https://www.ncbi.nlm.nih.gov/pubmed/8596596. https://doi.org/10.1056/NEJM199604113341504
59. Dimitriu-Leen AC, Scholte AJHA, van Rosendael AR, van den Hoogen IJ, Kharagjitsingh AV, Wolterbeek R, et al. Value of coronary computed tomography angiography in tailoring aspirin therapy for primary prevention of atherosclerotic events in patients at high risk with diabetes mellitus. Am J Cardiol. 2016; 117: 887-93. https://www.ncbi.nlm.nih.gov/pubmed/26803383. https://doi.org/10.1016/j.amjcard.2015.12.023
60. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015; 313: 603-15. https://www.ncbi.nlm.nih.gov/pubmed/25668264. https://doi.org/10.1001/jama.2014.18574
61. Goldfine AB, Phua EJ, Abrahamson MJ. Glycemic mana¬gement in patients with coronary artery disease and prediabetes or type 2 diabetes mellitus. Circulation. 2014; 129: 2567-73. https://www.ncbi.nlm.nih.gov/pubmed/24934464. https://www.ncbi.nlm.nih.gov/pmc/articles/4401832. https://doi.org/10.1161/CIRCULATIONAHA.113.006634
62. Guha A, Harmancey R, Taegtmeyer H. Nonischemic heart failure in diabetes mellitus. Curr Opin Cardiol. 2008; 23(3): 241-8. https://www.ncbi.nlm.nih.gov/pubmed/18382213. https://www.ncbi.nlm.nih.gov/pmc/articles/3625426. https://doi.org/10.1097/HCO.0b013e3282fcc2fa
63. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; 377: 1228-39. https://www.ncbi.nlm.nih.gov/pubmed/28910237. https://doi.org/10.1056/NEJMoa1612917
64. Horr S, Nissen S. Managing hypertension in type 2 diabetes mellitus. Best Pract Res Clin Endocrinol Metab. 2016; 30(3): 445-54. https://www.ncbi.nlm.nih.gov/pubmed/27432077. https://doi.org/10.1016/j.beem.2016.06.001
65. Huang Y, Cai X, Chen P, Mai W, Tang H, Huang Y, Hu Y. Associations of prediabetes with all-cause and cardiovascular mortality: A meta-analysis. Annals of Medicine. 2014; 46: 684-92. https://www.ncbi.nlm.nih.gov/pubmed/25230915. https://doi.org/10.3109/07853890.2014.955051
66. Ishonina OG, Mikashinovich ZI, Olempieva EV, Kovalenko TD. Comparative characteristics of antioxidant status in women with diabetes type 2 of different age groups. Adv Gerontol. 2011;  24(4): 645-9. https://www.ncbi.nlm.nih.gov/pubmed/22550873
67. Kim H, Kim D, Cha B, Park TS, Kim KA, Kim DL, et al. Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea. J Diabetes Investig. 2014; 5(6): 701-8. https://www.ncbi.nlm.nih.gov/pubmed/25422771. https://www.ncbi.nlm.nih.gov/pmc/articles/4234234. https://doi.org/10.1111/jdi.12201
68. Kim DI, Yang HI, Park JH, Lee MK, Kang DW, Chae JS, et al. The association between resting heart rate and type 2 diabetes and hypertension in Korean adults. Heart. 2016; 9: 10-5. https://www.ncbi.nlm.nih.gov/pubmed/27312000. https://doi.org/10.1136/heartjnl-2015-309119
69. Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World J Diabetes. 2015; 25(6): 850-67. https://www.ncbi.nlm.nih.gov/pubmed/26131326. https://www.ncbi.nlm.nih.gov/pmc/articles/4478580. https://doi.org/10.4239/wjd.v6.i6.850
70. Luijks H, Schermer T, Bor H, van Weel C, Lagro-Janssen T, Biermans M, de Grauw W. Prevalence and incidence density rates of chronic comorbidity in type 2 diabetes patients: an exploratory cohort study. BMC Med. 2012; 10: 128. https://www.ncbi.nlm.nih.gov/pubmed/23106808. https://www.ncbi.nlm.nih.gov/pmc/articles/3523042. https://doi.org/10.1186/1741-7015-10-128
71. Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016; 164: 740-51. https://www.ncbi.nlm.nih.gov/pubmed/27088241. https://doi.org/10.7326/M15-2650
72. Matsue Y, Yoshida K, Nagahori W, Ohno M, Suzuki M, Matsumura A, et al. Peripheral microvascular dysfunction predicts residual risk in coronary artery disease patients on statin herapy. Atherosclerosis. 2014; 232(1): 186-90. https://www.ncbi.nlm.nih.gov/pubmed/24401235. https://doi.org/10.1016/j.atherosclerosis.2013.11.038
73. Mora S, Ames JM, Manson JE. Low-dose aspirin in the primary prevention of cardiovascular disease: shared decision making in clinical practice. JAMA. 2016; 316: 709-710. https://www.ncbi.nlm.nih.gov/pubmed/27323335. https://doi.org/10.1001/jama.2016.8362
74. Naito R, Kasai T. Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives. World J Cardiol. 2015; 7(3): 119-24. https://www.ncbi.nlm.nih.gov/pubmed/25810811. https://www.ncbi.nlm.nih.gov/pmc/articles/4365308. https://doi.org/10.4330/wjc.v7.i3.119
75. Neumiller JJ, Alicic RZ, Tuttle KR.. Therapeutic considerations for antihyperglycemic agents in diabetic kidney disease. J Am Soc Nephrol. 2017; 28: 2263-74. https://www.ncbi.nlm.nih.gov/pubmed/28465376. https://www.ncbi.nlm.nih.gov/pmc/articles/5533243. https://doi.org/10.1681/ASN.2016121372
76. Nwaneri C, Cooper H, Bowen-Jones D. Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. Br J Diabetes Vasc Dis. 2013; 13: 192-207. https://doi.org/10.1177/1474651413495703
77. Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. 2016; 316: 313-24. https://www.ncbi.nlm.nih.gov/pubmed/27434443. https://doi.org/10.1001/jama.2016.9400
78. Pareek A, Chandurkar NB, Salkar HR, Borkar MS, Tiwari D. Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type 2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin. Am J Ther. 2013; 20(1): 41-7. https://www.ncbi.nlm.nih.gov/pubmed/21326082. https://doi.org/10.1097/MJT.0b013e3181ff7c63
79. Pham I, Cosson E, Nguyen M, Valensi P. Evidence for a Specific Diabetic Cardiomyopathy: An Observational Retrospective Echocardiography Study in 656 Asymptomatic Type 2 Diabetic Patients. Internal Journal of Endocrinology. 2015; 2015: 1-8. https://doi.org/10.1155/2015/743503
80. Poupel L, Boissonnas A, Hermand P, Dorgham K, Guyon E, Auvynet C, et al. Pharmacological inhibition of the chemokine receptor, CX3CR1, reduces atherosclerosis in mice. Arteriosclerosis, Thrombosis and Vascular Biology. 2013; 33: 2297-305. https://www.ncbi.nlm.nih.gov/pubmed/23887641. https://doi.org/10.1161/ATVBAHA.112.300930
81. Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017; 376: 1407-18. https://www.ncbi.nlm.nih.gov/pubmed/28402770. https://doi.org/10.1056/NEJMoa1608664
82. Regidor E, Franch J, Seguí M, Serrano R, Rodríguez-Artalejo F, Artola S. Traditional risk factors alone could not explain the excess mortality in patients with diabetes: a national cohort study of older Spanish adults. Diabetes Care. 2012; 35: 2503-9. https://www.ncbi.nlm.nih.gov/pubmed/22875228. https://www.ncbi.nlm.nih.gov/pmc/articles/3507605. https://doi.org/10.2337/dc11-1615
83. Rodriguez-Poncelas A, Coll-de-Tuero G, Saez M, Garrido-Martín JM, Millaruelo-Trillo JM, Barrot de-la-Puente J, et al. Comparison of different vascular risk engines in the identification of type 2 diabetes patients with high cardiovascular risk. BMC Cardiovasc Disord. 2015; 15(1): 121. https://www.ncbi.nlm.nih.gov/pubmed/26464076. https://www.ncbi.nlm.nih.gov/pmc/articles/4605091. https://doi.org/10.1186/s12872-015-0120-3
84. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013; 34: 3035-87. https://www.ncbi.nlm.nih.gov/pubmed/23996285. https://doi.org/10.1093/eurheartj/eht108
85. Schneider AL, Kalyani RR, Golden S, Stearns SC, Wruck L, Yeh HC, et al. Diabetes and Prediabetes and Risk of Hospitalization: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2016; 39(5): 772-9. https://www.ncbi.nlm.nih.gov/pubmed/26953170. https://www.ncbi.nlm.nih.gov/pmc/articles/4839170. https://doi.org/10.2337/dc15-1335
86. Shah R, Hinkle CC, Ferguson JF, Mehta NN, Li M, Qu L, et al. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes. 2011; 60: 1512-8. https://www.ncbi.nlm.nih.gov/pubmed/21525510. https://www.ncbi.nlm.nih.gov/pmc/articles/3292325. https://doi.org/10.2337/db10-0956
87. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1,9 million people. Lancet. 2015; 385 Suppl 1: S86. https://www.ncbi.nlm.nih.gov/pubmed/26312908. https://doi.org/10.1016/S0140-6736(15)60401-9
88. Shen L, Shah BR, Reyes EM, Thomas L, Wojdyla D, Diem P, et al. Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ. 2013; 347: f6745. https://doi.org/10.1136/bmj.f67
89. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. The Lancet. 2012; 380(9855): 1741-8. https://www.ncbi.nlm.nih.gov/pubmed/23040422. https://www.ncbi.nlm.nih.gov/pmc/articles/3607818. https://doi.org/10.1016/S0140-6736(12)61422-6
90. Standards of medical care in diabetes — 2016. American Diabetes Association. Diabetes Care. 2016; 39(Suppl 1): 1-109.
91. Sung KC, Rhee ЕJ, Ryu S, Kim BJ, Kim BS, Lee WY, et al. Increased Cardiovascular Mortality in Subjects With Metabolic Syndrome Is Largely Attributable to Diabetes and Hypertension in 159 971 Korean Adults. J Clin Endocrinol Metab. 2015; 100(7): 2606–12. https://www.ncbi.nlm.nih.gov/pubmed/25993638. https://doi.org/10.1210/jc.2014-4031
92. Tappia PS, Dent MR, Dhalla NS. Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic Biol Med. 2006; 41: 349-61. https://www.ncbi.nlm.nih.gov/pubmed/16843818. https://doi.org/10.1016/j.freeradbiomed.2006.03.025
93. Teljeur C, Smith SM, Paul G, Kelly A, O'Dowd T. Multimorbidity in a cohort of patients with type 2 diabetes. Eur J Gen Pract. 2013; 19: 17-22. https://www.ncbi.nlm.nih.gov/pubmed/23432037. https://doi.org/10.3109/13814788.2012.714768
94. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014; 37: 2864-83. https://www.ncbi.nlm.nih.gov/pubmed/25249672. https://www.ncbi.nlm.nih.gov/pmc/articles/4170131. https://doi.org/10.2337/dc14-1296
95. Vaduganathan M, Claggett BL, Chatterjee NA. et al. Raptova smert sered patsiyentiv iz SN zi zberezhenoyu FV: analiz doslidzhennya TORSAT. Sertseva nedostatnist ta komorbidni stany. 2018; 1: 46. [Ukrainian]
96. Vinagre I, Mata-Cases M, Hermosilla E, Morros R, Fina F, Rosell M, et al. Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain). Diabetes Care. 2012; 35: 774-9. https://www.ncbi.nlm.nih.gov/pubmed/22344609. https://www.ncbi.nlm.nih.gov/pmc/articles/3308283. https://doi.org/10.2337/dc11-1679
97. Vorsanger MH, Subramanyam P, Weintraub HS, Lamm SH, Underberg JA, Gianos E, et al. Cardiovascular Effects of the New Weight Loss Agents. J Am Coll Cardiol. 2016; 68: 849-59. https://www.ncbi.nlm.nih.gov/pubmed/27539178. https://doi.org/10.1016/j.jacc.2016.06.007
98. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med. 2011; 171: 404-10. https://www.ncbi.nlm.nih.gov/pubmed/21403036. https://doi.org/10.1001/archinternmed.2011.2
99. Wilkin TJ. The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes. Int J Obes (Lond). 2009; 33: 716-26. https://www.ncbi.nlm.nih.gov/pubmed/19506563. https://doi.org/10.1038/ijo.2009.97
100. Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 Randomized Clinical Trial. JAMA. 2017; 318: 45-56. https://www.ncbi.nlm.nih.gov/pubmed/28672317. https://www.ncbi.nlm.nih.gov/pmc/articles/5817473. https://doi.org/10.1001/jama.2017.7117
101. Zhang Y, Janssen P, Wingler K, Schmidt HH, Moens AL. Modulating endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy. Am J Physiol Heart Circ Physiol. 2011; 301: H634-H646. https://www.ncbi.nlm.nih.gov/pubmed/21622818. https://doi.org/10.1152/ajpheart.01315.2010
102. Zhu H, Zhu S, Zhang X, Guo Y, Shi Y, Chen Z, Leung SW. Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials. Diabetology and Metabolic Syndrome. 2013; 5: 70. https://www.ncbi.nlm.nih.gov/pubmed/24228743. https://www.ncbi.nlm.nih.gov/pmc/articles/3834882. https://doi.org/10.1186/1758-5996-5-70